Zobrazeno 1 - 8
of 8
pro vyhledávání: '"J. C. Álvarez Cermeño"'
Autor:
J E Meca-Lallana, C Oreja-Guevara, D Muñoz, J Olascoaga, A Pato, L Ramió-Torrentà, V Meca-Lallana, M A Hernández, M E Marzo, J C Álvarez-Cermeño, A Rodríguez-Antigüedad, X Montalbán, O Fernández, Spanish GILENYA Registry Investigators
Publikováno v:
PLoS ONE, Vol 16, Iss 10, p e0258437 (2021)
ObjectiveTo describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.MethodsAn observational, re
Externí odkaz:
https://doaj.org/article/07987836f8b74fd78ad563e5d9b47c6e
Autor:
J E, Meca-Lallana, M, Fernández-Prada, E, García Vázquez, S, Moreno Guillén, S, Otero Romero, M, Rus Hidalgo, L M, Villar Guimerans, S, Eichau Madueño, Ó, Fernández Fernández, G, Izquierdo Ayuso, J C, Álvarez Cermeño, C, Arnal García, R, Arroyo González, L, Brieva Ruiz, C, Calles Hernández, A, García Merino, M, González Plata, M Á, Hernández Pérez, E, Moral Torres, J, Olascoaga Urtaza, P, Oliva-Nacarino, C, Oreja-Guevara, R, Ortiz Castillo, A, Oterino, J M, Prieto González, L, Ramió-Torrentá, A, Rodríguez-Antigüedad, A, Saiz, M, Tintoré, X, Montalbán Gairin
Publikováno v:
Scientia
Alemtuzumab; Eficacia; Práctica clínica habitual Alemtuzumab; Effectiveness; Daily clinical practice Alemtuzumab; Eficàcia; Pràctica clínica habitual Introduction Alemtuzumab is a highly effective drug approved by the European Medicines Agency a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5f910a7c2b129ab716f3d6f5dc7e6f8
https://doi.org/10.1016/j.nrleng.2019.11.001
https://doi.org/10.1016/j.nrleng.2019.11.001
Autor:
A Oterino, S. Moreno Guillén, G. Izquierdo Ayuso, M. González Platas, M. Rus Hidalgo, O. Fernández Fernández, J.M. Prieto González, S. Eichau Madueño, Alfredo Rodríguez-Antigüedad, E. Moral Torres, Lluís Ramió-Torrentà, J. Olascoaga Urtaza, X. Montalbán Gairin, J. C. Álvarez Cermeño, José Meca-Lallana, E. García Vázquez, R. Arroyo González, R. Ortiz Castillo, L. Brieva Ruiz, Celia Oreja-Guevara, L.M. Villar Guimerans, A. Saiz, S. Otero Romero, A. García Merino, M.A. Hernández Pérez, P. Oliva-Nacarino, C. Arnal García, M. Fernández-Prada, M. Tintoré, C. Calles Hernández
Publikováno v:
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Universidad Autónoma de Madrid
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Introducción: Alemtuzumab es un fármaco de alta eficacia aprobado por la Agencia Europeade Medicamentos como tratamiento modificador de la enfermedad en pacientes con esclerosismúltiple remitente recurrente.Objetivo: Elaborar un documento de conse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc39c60acae89afccf2404510b3e6a15
https://ddd.uab.cat/record/275788
https://ddd.uab.cat/record/275788
Autor:
C, Oreja-Guevara, J A, García-Merino, A, Saiz, A, Rodríguez-Antigüedad, J C, Álvarez-Cermeño, V, Estrada-Pérez, G, Izquierdo, O, Fernández
Publikováno v:
Revista de neurologia. 69(s02)
Cladribine is a prodrug, a synthetic analogue of deoxyadenosine, approved for use as selective immune reconstitution therapy in very active recurring multiple sclerosis in adults.To review the development of the drug, its mechanism of action and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::698f4f26a7d6550568456000ccacd838
https://pubmed.ncbi.nlm.nih.gov/31933293
https://pubmed.ncbi.nlm.nih.gov/31933293
Autor:
L, Ramió-Torrentà, J C, Álvarez-Cermeño, R, Arroyo, B, Casanova-Estruch, O, Fernández, J A, García-Merino, M A, Hernández, G, Izquierdo, S, Martínez-Yélamos, J, Meca, E, Moral, J, Olascoaga, J M, Prieto, A, Saiz
Publikováno v:
Neurologia (Barcelona, Spain). 33(5)
Gait impairment, a frequent sign in multiple sclerosis (MS), places a major burden on patients since it results in progressive loss of personal and social autonomy, along with work productivity. This guide aims to provide recommendations on how to ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::17557d80613aad794da1bcd1b5fee7c0
https://pubmed.ncbi.nlm.nih.gov/26873645
https://pubmed.ncbi.nlm.nih.gov/26873645
Autor:
O, Fernández, J A, García-Merino, R, Arroyo, J C, Álvarez-Cermeño, G, Izquierdo, A, Saiz, J, Olascoaga, A, Rodríguez-Antigüedad, J M, Prieto, C, Oreja-Guevara, M A, Hernández, E, Moral, J, Meca, X, Montalbán
Publikováno v:
Neurologia (Barcelona, Spain). 30(5)
Natalizumab treatment has been shown to be very efficacious in clinical trials and very effective in clinical practice in patients with relapsing-remitting multiple sclerosis, by reducing relapses, slowing disease progression, and improving magnetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4839ef3260359eeab3346a9d95117883
https://pubmed.ncbi.nlm.nih.gov/24360652
https://pubmed.ncbi.nlm.nih.gov/24360652
Autor:
O, Fernández, J A, García-Merino, R, Arroyo, J C, Álvarez-Cermeño, T, Arbizu, G, Izquierdo, A, Saiz, J, Olascoaga, A, Rodríguez-Antigüedad, J M, Prieto, C, Oreja-Guevara, M A, Hernández, X, Montalbán
Publikováno v:
Neurologia (Barcelona, Spain). 27(7)
Natalizumab is very effective at reducing relapses and delaying disease progression in patients with relapsing-remitting multiple sclerosis (RRMS). However, treatment has also been associated with a risk of progressive multifocal leukoencephalopathy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4dfb30b4e83b6d032fdf5179788c78d3
https://pubmed.ncbi.nlm.nih.gov/22078648
https://pubmed.ncbi.nlm.nih.gov/22078648
Publikováno v:
Neurology. 51(1)
Headache with neurologic deficits and lymphocytosis (HaNDL) is characterized by recurrent episodes of migraine-like headache associated with reversible neurologic deficits and CSF lymphocytosis. Recently, Berg and Williams1 established the diagnostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb86b381240b6760849b78b485d34aaf
https://pubmed.ncbi.nlm.nih.gov/9674832
https://pubmed.ncbi.nlm.nih.gov/9674832